Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
It's Not Just the Scale: Supporting Sustainable Change in Obesity Treatment
Beyond the Endpoint
32 minutes 14 seconds
1 month ago
It's Not Just the Scale: Supporting Sustainable Change in Obesity Treatment
In the first of a three-part series on obesity and GLP-1 medications, our guest Jennifer Norris shares the evolving landscape of obesity treatment. The conversation addresses common misconceptions and examines how GLP-1 medications, such as Ozempic, have transformed care alongside surgery and lifestyle interventions.
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
